Skip to main content

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

Recruiting · Phase 2, Phase 3 · NCT05491525

Conditions: Neurogenic Detrusor Overactivity

At a glance

Research payments reported, 2025
$151,434
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
71

About the trial

Sponsor
Urovant Sciences GmbH (with Sumitomo Pharma America, Inc.)
Tested
Vibegron (drug)
Dates
Started 2022-10-12; completion 2030-09
Results posted
Not yet

The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC

From ClinicalTrials.gov, last updated 2026-06-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sumitomo Pharma America, Inc. reported $151,434 in research payments for this study in 2025 (26 payments).

Products named: Gemtesa

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • The Nemours Foundation $51,498
  • Childrens Hospital Orange County $36,666
  • Duke University $18,973
  • The Research Foundation for The State University of New York $12,100
  • Childrens Hospital Colorado $10,191
  • Childrens Hospital $8,235
  • Arkansas Childrens Research Institute $6,725
  • Board of Regents of the Universty of Oklahoma Health Sciences Center $3,771
  • Albany Medical College $2,270
  • Wichita Urology Group PA $1,005

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.